Az Üzleti Sajtószolgálat (Original Text Service - OTS) üzleti vállakozások, cégek, intézmények közleményeit, tájékoztatóit, meghívóit, állásfoglalásait közli. Szolgáltatásunk segítségével több mint 2000 újságírót és kommunikációs szakembert érhet el könnyen, gyorsan és költséghatékonyan – az Ön által megfogalmazott sajtóközleményt változtatás nélkül juttatjuk el az MTI-előfizetők szerkesztőségi rendszerébe vagy igény szerint akár a külföldi sajtóhoz is. (Az OTS anyagai nem képezik az MTI-kiadás részét, a szó szerint továbbított szövegekért minden esetben a közlő a felelős.)
|
|
|
2021. október 4., hétfő 09:42 |
Debiopharm encourages breakthrough cancer research in Japan through its competitive JCA Mauvernay Award |
|
Lausanne, Switzerland, 4 October, 2021 (APA/OTS) - Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company, today announced the two winners of the 17th annual JCA Mauvernay Award for breakthrough Japanese oncology research projects in 2 categories: Innovative and/or Disruptive Research - Dr. Shumpei Ishikawa and Translational Research - Dr. Hiromichi Ebi. The winners were honored with trophies and a monetary prize during the hybrid (virtual/live) meeting of the 80th Annual Meeting of the Japanese Cancer Association (JCA) on Saturday, October 2nd in Yokohama, Japan by Prof. Hideyuki Saya President of the JCA and Dr. Takato Noumi, Debiopharm's representative in Japan along with Thierry Mauvernay, President of Debiopharm, Bertrand Ducrey CEO of Debiopharm who joined virtually. |
"Japan and Switzerland share several common values such as
commitment to excellence and professional diligence. That's one of
the reasons why I believe Japanese research continues to excel and
surpass our expectations," expressed Thierry Mauvernay, president of
Debiopharm. "It is our honor to award these two new JCA Mauvernay
Award winners and realize what their early research could mean for
patients in the future through further development."
"We were impressed with the potential implications of Dr.Ishikawa
and Dr. Ebi in different cancer types. Cancer remains the leading
cause of death worldwide so it deserves the deep exploration by
great minds in order to come closer to a cure. Japanese cancer
researchers continue to capture the attention of the international
community as seen in several of the past Nobel Peace Prizes in
Medicine. So, we are very pleased to continue to this important
award and hope to spark further collaboration," explained Bertrand
Ducrey, CEO of Debiopharm.
Dr. Shumpei Ishikawa's disruptive research at the University of
Toyko, is offering new insights into an aggressive form of gastric
cancer, diffuse-type gastric carcinoma (DGC), by exploring the
genomic characterization the cancer's life cycle. His comprehensive
characterization of DGC includes the identification of genes that
drive the transformation of cells to cancer cells (oncogenes), the
molecular and cellular dissection of the tumor microenvironment and
the environmental factors contributing to the disease. This holistic
approach has led to several influential discoveries that have been
published in top-ranking scientific journals.
Dr. Hiromichi Ebi's translational research at the Aichi Cancer
Center Research Institute is examining the development of targeted
therapies against tumor with aberrant MAPK signaling. His work is
focusing on the elucidation of the molecular mechanisms underlying
the differential clinical activities of drugs targeting mutated
oncogenes depending on the cancerous tissue and the tumor
microenvironment.
The JCA-Mauvernay Award Since 2005, the Japanese Cancer Association (JCA) and Debiopharm
Group have co-organized the 'JCA-Mauvernay Award'. This prize
illustrates the curiosity that drives researchers as well as the
scientific cooperation between Japan and Switzerland. It aims at
recognizing outstanding achievements in the field of oncology
amongst Japanese researchers, in both the fundamental and the
clinical aspects. The award has a total value of CHF 25'000.
Debiopharm's commitment to patients Debiopharm develops innovative therapies that target high unmet
medical needs in oncology and infectious diseases. Bridging the gap
between disruptive discovery products and real-world patient reach,
we identify high-potential compounds and technologies for
in-licensing, clinically demonstrate their safety and efficacy and
then select large pharmaceutical commercialization partners to
maximize patient access globally.
For more information, please visit www.debiopharm.com
We are on Twitter. Follow us @DebiopharmNews at
http://twitter.com/DebiopharmNews
Debiopharm Contact Dawn Haughton-Bonine Communication Manager dawn.bonine@debiopharm.com Tel: +41 (0)21 321 01 11
-------------------------------------------------------------------
Az OTS internetes oldalán található hírek, közlemények, fotók
a forrásmegjelöléssel (OTS) szabadon és korlátozás nélkül
felhasználhatók. Továbbközlés esetén a közzétevő köteles az átvett
anyagot tartalmának torzítása nélkül, félreérthetőséget,
rosszindulatú következtetéseket kizáró, az eredeti
szövegkörnyezetnek megfelelő módon feldolgozni és megjelentetni.
Az OTS hírek nem képezik az MTI hírkiadás részét, az MTI
által szó szerint továbbított tartalomért minden esetben a beadó a
felelős. © Copyright MTI nonprofit Zrt.
Az OTS szolgáltatással kapcsolatban további információt a
(06-1) 441-9050 telefonszámon vagy a ots@mti.hu elektronikus
levelező címen kaphat.
|
|
|
|
|
|
|
|
|
|
|